1105 no special intervention is required. If ventilation is inadequate from the start or if arterial Po. deteriorates more aggressive treatment is indicated. Mechanical ventilation with positive-endexpiratory-pressure is required,21 23 titrating the amount of pressure to produce the minimum amount of intrapulmonary shunt.2' The use of corticosteroids is not routinely recommended, although their place in the patient with true secondary drowning has not been studied in any large series.
(Accepted 18 September 1980)
SHORT REPORTS Injection abscesses in a diabetic due to Mycobacterium chelonei var abscessus
Most diabetics do not sterilise their hypodermic syringes before each insulin injection. They use glass syringes, sterilise them at intervals, and keep them in disinfectant. We report the case of an insulin-dependent diabetic who stored her glass syringe in disinfectant which was inadvertently inactivated and who developed multiple injection abscesses caused by Mycobacterium chelonei, var abscessus.
Case report
The patient, a 24-year-old English woman whose diabetes was diagnosed in 1968, first noticed a lesion on the upper lateral aspect of her right thigh in October 1979. At this time she was using both thighs as insulin injection sites. The lesion was deeply subcutaneous, painful, indurated, roughly 2 cm x 3 cm in size, and the overlying skin was warm and discoloured, breaking down after two weeks with a central discharging sinus. Routine culture of sinus pus did not detect any recognised bacterial pathogens. A course of flucloxacillin was ineffectual. A similar lesion developed after two weeks on the opposite thigh, and culture of pus taken from it yielded an anaerobic coccus (Peptococcus spp). She was treated with metronidazole for five weeks with no perceptible effect upon the lesions. In November 1979 each of them had extended deep satellite lesions into the surrounding subcutaneous tissues, and one of these broke through to the surface, discharging buff-coloured creamy pus. In February 1980, after five weeks' incubation at 30°C, a Lowenstein Jensen culture of pus draining from the original abscess on the right thigh yielded a growth of an atypical mycobacterium. The organism was identified by Dulwich Regional Tuberculosis Laboratory and by Dr Phenylbutazone poisoning is uncommon and apparently has not been reported in the United Kingdom. We report the case of a patient with very abnormal phenylbutazone metabolism in whom hepatic and renal damage occurred.
A previously healthy 17-year-old girl was admitted 16 hours after allegedly taking 40 phenylbutazone tablets (8 g). She did not drink alcohol or take any drugs regularly and the tablets had belonged to her mother. The patient initially fell asleep but woke feeling very unwell with severe nausea. On examination she was drowsy with nystagmus. Intravenous fluids were started because of persistent vomiting. The next morning she developed a sinus tachycardia (120/min) and was hyperventilating with a respiratory aLkalosis (arterial H+ 32 nmol/l (pH 7.49), Pco2 2 9 kPa (22 mm Hg), and bicarbonate 17 mmol(mEq)/l). Malaise, drowsiness, and vomiting continued for three days, when jaundice appeared with biochemical evidence of liver damage (figure). The maximum plasma bilirubin concentration, alanine aminotransferase activity, and alkaline phosphatase concentration were 125 ,umol/l (7-4 mg/100 ml), 471 U/1, and 136 U/l on the 4th, 6th, and 8th days respectively. Tests for hepatitis B surface antigen and antibody were negative and there was no evidence of haemolysis or other haematological toxicity. The plasma albumin concentration remained within normal limits and there was no clinical evidence of fluid retention. Despite adequate fluid replacement there was early but transient impairment of renal function with proteinuria, a reduction in creatinine clearance to 34 ml/min, and a raised plasma urea concentration ( figure) .
The patient subsequently improved and was discharged on the sixth day, although liver function tests were still abnormal at follow-up nine days later. Serial plasma concentrations of phenylbutazone and its metabolites oxyphenbutazone and y-hydroxyphenylbutazone were measured simultaneously by high performance liquid chromatography.' The initial plasma phenylbutazone concentration was grossly raised at 670 ,g/ml and the half life, normally about three days, was very short at 23 hours. In contrast to the pattern of metabolites in plasma after therapeutic doses of phenylbutazone2 the relative proportions of oxyphenbutazone and y-hydroxyphenylbutazone were reversed, with the former disappearing rapidly and high concentrations of the latter, which rapidly exceeded those of the parent drug (figure).
Comment
The clinical features in this patient resembled those described in the few previous reports of phenylbutazone intoxication, although jaundice does not always occur. Convulsions and gastrointestinal perforation have also been reported. [3] [4] [5] respectively of the total in plasma, and the maximum for y-hydroxyphenylbutazone was 6%. Thus in our patient the pattern of metabolites was completely reversed. Possible explanations include greatly increased production of y-hydroxyphenylbutazone, concentrationdependent saturation of aromatic hydroxylation, and impaired renal excretion of the y-hydroxy metabolite. The kinetics, however, were not consistent with saturation, and increased y-hydroxylation seems the most likely cause in view of the unusually short half life of the parent drug. The hepatotoxicity of phenylbutazone may be mediated through metabolic activation (as with paracetamol), and we are tempted to postulate a relationship between abnormal metabolism of the drug in this patient and subsequent liver damage.
